$TMO

Pettiti Gianluca sold $226K of TMO

Pettiti Gianluca (President & COO) sold 400 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $565.00 ($0.23M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pettiti Gianluca
Published Jul 28, 2026, 8:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
high confidence
Mentioned
$TMO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

This provides confirmation of a planned insider sale, with limited implications for near-term valuation or operating outlook.

02

Market read

Traders may note the insider sale for sentiment, but the planned nature and modest dollar value suggest low fundamental impact.

03

What to watch

The sale is explicitly under a pre-arranged 10b5-1 plan, which often reduces interpretability versus discretionary sales.

Relevance 3/10Novelty 2/10Timing: after-hours filing timestamp on 2026-07-28

Background

The article is a SEC Form 4 disclosure of an insider open-market sale by Thermo Fisher’s President and COO.

Company-level read

Ticker impact

$TMONeutralHigh confidence
Context

Thermo Fisher insider Pettiti Gianluca, President and COO, sold 400 shares at $565 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the disclosed sale size ($226k) is small relative to company scale.

Market effects

No direct sector read-through; this is company-specific insider liquidity.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as reduced confidence, though this specific disclosure is not large or unscheduled.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • Pettiti Gianluca

    President and COO who sold 400 shares at $565 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DALMed

CNBC’s ‘Final Trades’: Delta Air, Target, Thermo Fisher Scientific - Delta Air Lines (NYSE:DAL)

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

$BIIBMed

Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.